Background: Alopecia areata (AA) is an autoimmune-mediated hair follicle disorder. In the literature, there is no study evaluating metabolic syndrome and levels of ischemia-modified albumin (IMA) which is proposed as an oxidative stress biomarker in patients with AA. Aims: The aim was to investigate the presence of metabolic syndrome and the levels of IMA, small dense low-density lipoprotein (sd-LDL), and visfatin levels in AA patients. Settings and Design: A hospital-based cross-sectional study was undertaken among AA patients and controls. Subjects and Methods: Thirty-five patients with AA and 35 sex-, age-, and body mass index-matched healthy controls were enrolled. Clinical and laboratory parameters of metabolic syndrome were examined in all participants. Furthermore, IMA, sd-LDL, and visfatin levels were assessed and analyzed with regard to disease pattern, severity and extent, severity of alopecia tool score, duration, and recurrence. Results:
Introduction
Alopecia areata (AA), characterized by sudden onset of oval or round alopecic patches, is believed to be an organ-specific autoimmune disorder with a genetic background. [1] Recently, some oxidative stress molecules have been suggested as biomarkers of disease activity and prognosis. [2] Ischemia-modified albumin (IMA) is raised in higher oxidative stress condition, including type-2 diabetes, hypercholesterolemia, and obesity, and is believed to be an oxidative stress marker in many systemic inflammatory disorders. [3, 4] In addition, it has been shown that metabolic processes within the cholesterol synthesis pathway may directly influence hair growth through particular signaling molecules. [5] Insulin resistance has been observed in patients with AA. [6] Recently, Lim et al. suggested possible metabolic comorbidities, including hyperlipidemia in AA. [7] Increased level of small dense low-density lipoprotein cholesterol (sd-LDL-C) is one of the main components of atherogenic dyslipidemia. [8] There are limited data available regarding the relationship among metabolic conditions, cardiovascular diseases, and AA. In addition, recent trials have shown increased lipid peroxidation and defective antioxidant activity in patients with AA. [9] Based on these findings, we aimed to investigate few markers associated with ischemia, oxidative stress, atherogenic hyperlipidemia, and inflammation, as well as their relationship with disease characteristics in AA. To the best of our knowledge, sd-LDL, IMA, and visfatin levels of AA patients have not been studied previously. In the present research, we conducted a case-control study to evaluate the clinical and laboratory parameters of metabolic syndrome as well as sd-LDL, IMA, and visfatin levels in AA patients.
Subjects and Methods

Study population
Patients who presented with hair loss to our department and were diagnosed with AA during January 2017 to December 2017 were included in the study. Thirty-five patients (17 women and 18 men) and 35 age-, sex-, and body mass index (BMI)-matched controls (17 women and 18 men) who fulfilled the inclusion criteria were enrolled. The control group comprised of healthy volunteers who presented with cosmetic complaints.
All the participants were ≥18 year old and were made to undergo systemic and dermatological examinations. Patients with spontaneous hair regrowth at the initial presentation were not included in the study. The exclusion criteria were pregnancy, lactation, history of active or chronic infection, malignancy, ischemic cardiovascular diseases, and hypertension. Factors, such as history of diabetes and thyroid disorders, were matched between the two groups. A family history of AA, premature (≤49 years) cardiovascular diseases, and autoimmune disorders, including atopic dermatitis, allergic rhinitis, asthma, thyroid disease, vitiligo, and diabetes were recorded. Participants with a family history of AA were not included as healthy controls. The demographic characteristics as well as the physical exercise habits and attitudes of the participants in the two groups were noted.
Patients were categorized into subclasses as per the Severity of Alopecia Tool (SALT) scores (S0, no hair loss; S1, <25% hair loss; S2, 25%-49% hair loss; S3, 50%-74% hair loss; S4, 75%-99% hair loss; and S5, 100% hair loss) defined by Olsen et al. [10] Disease characteristics, including the duration of current disease episode, total number of episodes, age at disease onset, pattern of scalp hair loss, presence of positive pull test, AA severity, SALT subclasses, eyebrow involvement, beard involvement, body hair loss, nail involvement, as well as previous and current treatment modalities were noted. Severity of AA was determined as described by Kavak et al. [11] Duration of the current episode was defined as the time from disease onset to the time of first admission of the patient in the study.
Measurements and sample collection
Waist circumference (WC, cm), height (m), weight (kg), systolic blood pressure (normal: 90-120 mmHg), and diastolic blood pressure (normal: 60-80 mmHg) were measured. The BMI (kg/m 2 ) was calculated using the Quetelet index for each participant. [12] All the blood samples (10 ml of peripheral venous blood) from all participants were collected using biochemistry tubes (BD Vacutainer ® SST TM II Advance serum tube, 367955 -13×100 mm×5 ml, BD-Belliver Industrial Estate, Plymouth PL6 7BP, UK) in the morning after an overnight fast. Fasting blood glucose (FBG), total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured using the enzymatic method. Serum albumin levels were analyzed using the nephelometric method. Levels of LDL-C were determined using Friedewald formula (LDL=total cholesterol -HDL − TG/5.0 [mg/dl]).
For the analyses of visfatin, sd-LDL, and IMA, blood samples were immediately centrifuged (Electromag M815, 1200 g-relative centrifugal force, for 10 min); thereafter, the sera were separated. Samples were stored at −80°C. Serum visfatin levels were quantified using the sandwich enzyme-linked immunosorbent assay method (Elabscience Biotechnology Co. Ltd. WuHan, P.R.C., Catalog No: E-EL-H1763, LOT: AK0017NOV20092). Sd-LDL-C levels were measured using the technique previously described by Hirano et al. [13] As defined by Bar-Or et al., rapid colorimetric assay that quantitatively measures unbound cobalt was used for calculating the IMA. The results are expressed in absorbance units. Adjusted IMA levels were calculated using the following formula: Individual albumin/median albumin concentration of the population×IMA.
The accepted normal ranges of the laboratory parameters in this study were as follows: FBG: 74-109 mg/dl; TG: 0-200 mg/dl; LDL-C: 0-100 mg/dl; HDL-C: 40-60 mg/dl; and Very LDL-C: 0-40 mg/dl. For each parameter, a value higher than the upper limit was categorized as "elevated."
Ethics
Written consent was obtained from all the studied patients and controls before data collection. The study protocol was approved by the Ankara Numune Training and Research Hospital Ethics Committee of Clinical Studies, code: E-16-1149. The study protocol was in accordance with the principles of the Helsinki Declaration of 1975.
Statistical analyses
Statistical analyses were performed using SPSS software (version 21.0 for Windows; SPSS Inc., Chicago, IL, USA). Parametric variables are presented as means and standard deviations and nonparametric variables are presented as medians and interquartile ranges (IQRs). Frequencies and percentages were calculated for the categorical variables. Chi-square or Fischer's exact test was used for analyzing the categorical variables. Kolmogorov-Smirnov and histogram analyses were used for determining whether the continuous variables were normally distributed. Normally distributed numeric variables were analyzed using Student's t-test and analysis of variance. Mann-Whitney U and Kruskal-Wallis tests were used for comparing the non-normally distributed numeric variables. Correlations of numeric variables were assessed using Spearman and Pearson tests. P<0.05 was considered statistically significant.
Results
Thirty-five AA patients, including 17 women (48.6%) and 18 men (51.4%) with a mean age ± standard deviation of 32.5±10.8 years, were included in the study. The median BMI values of the AA patients were 23.5 kg/m 2 (men) and 25 kg/m 2 (women). The controls were matched for age, sex, and BMI. Demographic, physical, and habitual characteristics as well as blood pressure values of both the groups are summarized in Table 1 . Both groups exhibited similar physical activity attitude. The prevalence of a family history of premature cardiovascular disease and personal history of comorbid diseases (asthma, thyroid disease, vitiligo, and diabetes mellitus) were similar. However, family history of AA and autoimmune diseases was observed more frequently in the AA group than in the healthy controls (P=0.003 and 0.002, respectively) [ Table 1 ]. No statistically significant difference was present in the prevalence of metabolic syndrome between the patients and healthy controls. The disease characteristics of the patients are presented in Table 2 .
Among all the parameters, the median values of the IMA and adjusted IMA of the patients were significantly different from those of the healthy controls (P<0.05 and P=0.002, respectively) [ Table 3 ]. The adjusted IMA levels did not correlate with disease duration (r=0.17, P=0.33), age at disease onset (r=0.05, P=0.75), number of alopecic patches (r=0.05, P=0.97), total episodes (r=0.12, P=0.47), AA severity (r=0.98, P=0.57), and SALT score (r=0. 19, P=0.16) . However, we found a significant positive correlation among the adjusted IMA levels, WCs (r=0.443, P=0.008), and TG levels (r=0.535, P=0.001) of the AA patients. Pull test positivity was associated with higher levels of adjusted IMA (P<0.05), while recurrence and presence of beard, eyebrow, body, or nail involvement showed no association. The IMA and adjusted IMA levels were similar between the male and female AA patients.
There was no significant difference in the median sd-LDL levels between the AA patients and healthy controls (P>0.05); however, we found a significant positive correlation between sd-LDL and adjusted IMA levels in AA patients (r=0.46, P<0.05). In AA patients, there was a significant difference in the sd-LDL levels of male (45 mg/dl IQR: 26) and female (36 mg/dl, IQR: 19) patients (P<0.05). The metabolic parameters of AA patients and healthy controls are summarized in Table 3 .
Discussion
The underlying causal mechanisms of AA remain unclear. The upregulation of immune mechanisms and disruption of the immune privilege of the hair follicle are believed to be the main causative pathogenetic mechanisms. The hair follicles that express low levels of major histocompatibility complex are attacked by autoreactive CD8+ T-lymphocytes. Peribulbar lymphocytic infiltration induces apoptosis of the keratinocytes of the follicle. Consequently, cell cycle inhibition within the hair matrix results in hair loss. [14] In addition, currently, oxidative stress is clearly implicated in AA pathogenesis based on genetic and molecular studies. [15, 16] The authors have also demonstrated increased levels of reactive oxygen species and increased oxidative stress in patients with AA. [17, 18] Increase in free-radical production may be a probable causative factor.
It is noteworthy that the association of AA with other immune disorders, such as systemic lupus erythematosus, celiac disease, thyroid disease, atopy, and vitiligo, supports the potential role of systemic inflammation in AA pathogenesis. [19] There are conflicting results in the literature regarding the metabolic profile and cardiovascular risk of AA patients. An association between AA and metabolic syndrome has been reported in a recent study. [20] Lim et al. found that the LDL levels of women with AA were higher than those of healthy women. [7] The authors clearly suggested a link among lipid metabolism, cholesterol biosynthesis, and hair disorders in this report. In contrast, the present study revealed that the lipid profiles of the AA patients and healthy controls were comparable. We also observed higher sd-LDL levels in male patients compared to those in female patients, indicating that sex influenced the serum sd-LDL levels. However, the present study did not find similar elevations in healthy men.
The adipose tissue serves as a dynamic endocrine tissue and performs functions beyond simple energy storage. It is involved in the production of several bioactive compounds called adipocytokines that regulate metabolic pathways. These adipocytokines are involved in metabolic disorders, such as insulin resistance and obesity as well as pro-inflammatory and autoimmune processes. [21] IMA is a modified form of human albumin that increases as a result of hypoxic and free-radical injury. [4] It is recommended to study the IMA results adjusted for albumin levels owing to the influence of albumin concentration on the IMA levels. [22, 23] It has been proposed as a marker of oxidative stress and the early diagnosis of acute coronary syndrome. With respect to systemic oxidative injury, the relationship between IMA and few inflammatory dermatologic conditions has been previously reported. [24, 25] To the best of our knowledge, our study is the first one to demonstrate a greater increase in the levels of IMA and adjusted IMA in AA patients than in age-, sex-, and BMI-matched healthy controls. It is noteworthy that the study groups in our series were comparable in terms of blood pressure, smoking and drinking habits, as well as the laboratory parameters of metabolic syndrome. Thus, we can hypothesize that these results may support the role of oxidative status in AA pathogenesis. In addition, the adjusted IMA levels were higher in patients with pull test positivity that might represent disease activity. There was no evidence of its relationship with the SALT score, disease severity, pattern, and disease duration. The relatively small sample size may be one of the reasons for these results.
Recently, few studies have addressed the risk of acute myocardial infarction and stroke in AA with conflicting results. [26, 27] Kang et al. detected an increased risk of stroke in AA patients. [27] Moreover, Wang et al. demonstrated increased expression of cardiac biomarker troponin in AA patients in a recent report. [28] In a recent study, hypertension and diabetes were more common in late-onset alopecia. [29] Sd-LDL is known to have atherogenic potential. [30] It is noteworthy that we detected a positive correlation between sd-LDL levels and adjusted IMA levels in AA patients. Personal history, family history, smoking and exercise-related attitudes, FBG, and lipid profile were similar to those in the age-, sex-and BMI-matched study groups of the present study; therefore, our findings might support the hypothesis that AA patients were predisposed to have atherogenic dyslipidemia and consequently ischemic complications.
The adipose tissue serves as a dynamic endocrine tissue and performs functions beyond simple energy storage. It is involved in the production of several bioactive compounds called adipocytokines that regulate metabolic pathways. These adipocytokines are involved in metabolic disorders, such as insulin resistance and obesity as well as pro-inflammatory and autoimmune processes. [21] Visfatin, a novel adipocytokine, has proinflammatory effects. [31] Recent studies have demonstrated that serum visfatin levels are increased in both T-helper (Th1) and Th2-mediated inflammatory disorders, including Behçet's disease, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma. [32] [33] [34] [35] On the contrary, in the current study, we did not find a significant difference in visfatin levels between the groups.
The main limitation of our single-center study is the relatively small sample size. The disease severity was mild to moderate in most patients; therefore, the disease subgroups were too small to allow statistical evaluation. Moreover, some metabolic parameters associated with insulin resistance and metabolic syndrome, including insulin levels, high-sensitive C-reactive protein, and glycosylated hemoglobin were not included.
Conclusions
Increasing evidences suggest the potential role of oxidant-antioxidant imbalance in AA. There are conflicting results in the literature regarding metabolic profiles and cardiovascular risk in AA patients. This study evaluated the prevalence of metabolic syndrome and demonstrated an increase in IMA and adjusted IMA levels in AA patients. We hypothesized that the oxidative process might be associated with disease activity in AA patients. Furthermore, increased IMA levels in these patients might reflect an increased risk of atherosclerosis and cardiovascular diseases. Future, large-scale prospective studies that eliminate the confounding factors are required for determining the exact relationship between AA and the ischemic process.
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